Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Accumulated Expenses: 2019-2024

  • Burning Rock Biotech's Accumulated Expenses fell 17.04% to $12.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $12.3 million, marking a year-over-year decrease of 17.04%. This contributed to the annual value of $12.3 million for FY2024, which is 17.04% down from last year.
  • Latest data reveals that Burning Rock Biotech reported Accumulated Expenses of $12.3 million as of Q4 2024, which was down 17.04% from $14.8 million recorded in Q4 2023.
  • In the past 5 years, Burning Rock Biotech's Accumulated Expenses registered a high of $25.2 million during Q4 2022, and its lowest value of $12.3 million during Q4 2024.
  • Over the past 3 years, Burning Rock Biotech's median Accumulated Expenses value was $14.8 million (recorded in 2023), while the average stood at $17.4 million.
  • Per our database at Business Quant, Burning Rock Biotech's Accumulated Expenses surged by 67.15% in 2020 and then plummeted by 41.36% in 2023.
  • Burning Rock Biotech's Accumulated Expenses (Quarterly) stood at $12.8 million in 2020, then spiked by 56.55% to $20.1 million in 2021, then grew by 25.58% to $25.2 million in 2022, then plummeted by 41.36% to $14.8 million in 2023, then fell by 17.04% to $12.3 million in 2024.
  • Its Accumulated Expenses was $12.3 million in Q4 2024, compared to $14.8 million in Q4 2023 and $25.2 million in Q4 2022.